Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Quest Diagnostics (DGX)
NYSE:DGX
Holding DGX?
Track your performance easily
Earnings Data
Report Date
Jan 30, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
$2.19Last Year’s EPS
$2.15Same Quarter Last Year
Moderate Buy
Based on 13 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 22, 2024
|% Change Since: 3.89%
|Next Earnings Date:Jan 30, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted strong revenue growth driven by acquisitions, advanced diagnostics, and operational improvements. However, challenges such as weather impacts, IT outages, and integration of acquisitions affected margins and may pose short-term hurdles.Company Guidance
During the Quest Diagnostics Q3 2024 earnings call, the company provided updated financial guidance for the full year. They anticipate revenues between $9.8 billion and $9.85 billion, with adjusted EPS expected to range from $8.85 to $8.95. The guidance reflects strong organic growth and the impact of recent acquisitions, such as LifeLabs, which contributed $70 million in revenue for five weeks during Q3. Quest also projects cash from operations to reach approximately $1.3 billion, with capital expenditures around $420 million. The company expects to complete eight acquisitions in 2024, exceeding their long-term growth target from acquisitions, with LifeLabs being a significant contributor. Despite challenges such as Hurricane Milton, which is expected to impact Q4 revenues by $15 million and EPS by $0.08, Quest maintains a positive outlook, reaffirming a long-term outlook of mid-single-digit revenue CAGR and high single-digit earnings CAGR from 2023 to 2026.Strong Revenue Growth
Total revenue growth of 8.5% including 4.2% organic growth, driven by new customer wins and acquisitions.
Significant Acquisitions
Completed 3 acquisitions in the quarter, including LifeLabs in Canada and Allina Health in the US. Plans to finalize 8 acquisitions by year-end.
Advanced Diagnostics Expansion
Double-digit revenue growth in advanced diagnostics, particularly in brain health and women's health.
Operational Excellence with Automation
Completed build-out of full end-to-end automation in Kansas lab, enhancing productivity and quality.
Consumer Platform Growth
Consumer platform questhealth.com grew revenues by more than 40% with increased repeat customer rate.
---
DGX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
DGX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 22, 2024 | $147.37 | $157.47 | +6.85% |
| Jul 23, 2024 | $146.62 | $140.26 | -4.34% |
| Apr 23, 2024 | $128.76 | $135.30 | +5.08% |
| Feb 01, 2024 | $126.39 | $125.15 | -0.98% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Quest Diagnostics (DGX) report earnings?
Quest Diagnostics (DGX) is schdueled to report earning on Jan 30, 2025, TBA Not Confirmed.
What is Quest Diagnostics (DGX) earnings time?
Quest Diagnostics (DGX) earnings time is at Jan 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is DGX EPS forecast?
DGX EPS forecast for the fiscal quarter 2024 (Q4) is $2.19.
---